Serum Institute of India partners with Univercells to make personalised cancer treatments more accessible
Singapore, April 12 -- Serum Institute of India (SII), the world's largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator, targeting a dramatic increase in accessibility to personalised cancer care. This partnership aims to bring cutting edge treatment options within reach of millions globally.
At present, personalised care options such as novel cancer vaccines and specialized immunotherapies are accessible to a few patients only. These new therapies are developed using genetic material extracted from the patient's tumors, a process which is both time-consuming, and expensive.
Besides, due to strict regulatory limitations on the sequence, transfer, and manufacturing of genetic material, these treat...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.